CLAIMS

1. A pharmaceutical aqueous solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.

2. A solution according to claim 1 the pH-value of the solution being in the range of from about 3 to about 4.2.

3. Aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.

4. A solution according to claim 3 the pH-value of the solution being in the range of from about 3 to about 4.2.

5. A solution according to claim 3 or 4, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

6. A pharmaceutical solution, particularly an intravenous infusion concentrate, comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,

(b) pharmaceutically acceptable organic solvent comprising ethanol,

(c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally

(d) a water-solubility enhancing agent.

7. A solution according to claim 6, wherein the amount of said solvent is 90 – 99.9 %, preferably 95 – 99.9 %, by weight of the solution.

8. A solution according to claim 6 or 7, wherein the amount of said organic acid is 0.005 – 2 %, preferably 0.01 – 1 %, by weight of the solution.

9. A solution according to any of claims 6 - 8, wherein pharmaceutically acceptable organic acid is a 2-hydroxy alkanoic acid.

10. A solution according to claim 9, wherein pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.

11. A solution according to claim 6, wherein the amount of the water-solubility enhancing agent is 0.1 – 5 % by weight.

12. A solution according to claim 6, wherein the water-solubility enhancing agent is polyvinylpyrrolidone.

13. A solution according to claim 6 comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof in amount of 0.01 – 1.0 % by weight,

(b) dehydrated ethanol in amount of 95 – 99.5 % by weight,

(c) citric acid in amount of 0.03 – 0.6 % by weight, and
(d) polyvinylpyrrolidone in amount of 0.5 – 2 % by weight.